High-dose immunoglobulin therapy in four patients with onyalai

Hesseling P.B. (1991)


Onyalai, a form of immune thrombocytopenia in Africa, has a recorded death rate of 9.8% in the acute phase due to haemorrhagic shock or central nervous system bleeding. Four patients with active bleeding and a mean platelet count of 6 x 109/litre were each treated with 0.67 g/kg intravenous globulin (Sandoglobulin®) daily on 3 successive days. Clinical bleeding ceased within 3 d and all patients responded with a rise in the platelet count, which peaked at 19-21 d. No side effect was recorded. Intravenous globulin therapy may reduce the morbidity of the acute phase of onyalai.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/14569
This item appears in the following collections: